Tagawa R et al
10.1136/gutjnl-2017-314352 78 ParamsothyS.KammM
doi: 10.1016/s0891-5849(02)01040-7
Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial
[225] In 2006, Lilly paid $700 million to settle around 8,000 of these lawsuits, [226] and in early 2007, Lilly settled around 18,000 suits for $500 million, which brought the total Lilly had paid to settle suits related to the drug to $1.2 billion
This approval is based on evidence from clinical trials demonstrating the drugs effectiveness in promoting significant weight loss in individuals with obesity or overweight, including those with weight-related health conditions such as type 2 diabetes, hypertension, or dyslipidemia